Komori
Other Disclosures4892Cyfuse Biomedical K.K.Pharmaceuticals

Notice regarding progress in the development of a new 3D cell product and recognition of non-operating income

Development of “three-dimensional stromal tissue,” a new 3D cell product being developed under a Tokyo Metropolitan Government grant program for use in evaluating intractable fibrotic diseases, has been completed. In connection with completion of the project, a ¥15 million grant will be recognized as non-operating income in the fourth quarter of the fiscal year ending December 2026.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
15000
¥ thousand
Wording
Conditional
How definitive the wording is.

Announced details

Three-dimensional stromal tissueFunctional Cellular Device (FCD®)Human 3D Mini-Liver®/Disease Model3D Mini-Intestinal Model
Applicable field (uses covered by this announcement)
Development of new drugs for intractable fibrotic diseasesDrug efficacy evaluationDevelopment of novel therapeuticsAlternatives to animal testing
Launch dateFrom December 2025 (actual: launch of sales of the Human 3D Mini-Liver®/Disease Model)
Relationship between the counterparty and the company
Cyfuse Biomedical K.K.4892
Relationship with the Company

The Company was selected for a public offering program administered by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation and received a grant.

CounterpartyTokyo Metropolitan Small and Medium Enterprise Promotion Corporation

Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation. Other information, including location, representative, business activities, capital and year established, is not disclosed.

Impact on Business Performance

The Company will recognize ¥15 million as non-operating income in the fourth quarter of the fiscal year ending December 2026. This amount has already been incorporated into the full-year earnings forecast for the fiscal year ending December 2026.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredThree-dimensional stromal tissue, Functional Cellular Device (FCD®), Human 3D Mini-Liver®/Disease Model, 3D Mini-Intestinal Model
CounterpartyTokyo Metropolitan Small and Medium Enterprise Promotion Corporation
Counterparty overviewTokyo Metropolitan Small and Medium Enterprise Promotion Corporation. Other information, including location, representative, business activities, capital and year established, is not disclosed.
Relationship with the CompanyThe Company was selected for a public offering program administered by the Tokyo Metropolitan Small and Medium Enterprise Promotion Corporation and received a grant.
Launch dateFrom December 2025 (actual: launch of sales of the Human 3D Mini-Liver®/Disease Model)
Applicable areaDevelopment of new drugs for intractable fibrotic diseases, Drug efficacy evaluation, Development of novel therapeutics, Alternatives to animal testing
Impact on Business PerformanceThe Company will recognize ¥15 million as non-operating income in the fourth quarter of the fiscal year ending December 2026. This amount has already been incorporated into the full-year earnings forecast for the fiscal year ending December 2026.
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The grant amount of ¥15 million was finalized following completion of the prescribed project and receipt of the final grant award notice.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding progress in the development of a new 3D cell product and recognition of non-operating income | Cyfuse Biomedical K.K. (4892) timely disclosure | Komori